In the biotechnology industry, Dendreon Corporation (NASDAQ:DNDN) was the most active and top gainer on Friday after hopes that more patients will be using its prostate cancer drug Provenge.
PharmAthene, Inc. (NYSEAMEX:PIP) was on the move after the Delaware Supreme Court heard oral arguments in continuing lawsuit with SIGA Technologies.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Amyris Inc (NASDAQ:AMRS) both got a boost on Friday after getting an upgrade from “neutral” to an “outperform” rating at Zacks.[article_detail_ad_1]
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) and Novavax, Inc. (NASDAQ:NVAX) both marked third rally in a row.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is again on gaining track after announcing interim results on Phase 2a trial of ACH-3102. Following the news, the stock traded lower only on Thursday.
Another noteworthy gainer Cell Therapeutics Inc (NASDAQ:CTIC) jumped 17.83% last week after beginning enrollment in pacritinib Phase 3 trial for myelofibrosis.
BioTime, Inc. (NYSEAMEX:BTX) extended four-day winning streak after submitting a Clinical Investigation Protocol (CIP) to European regulatory authorities for approval to begin trials for its Renevia stem cell delivery platform.
Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) advanced 2.68% after adding Genzyme’s President and CEO David Meeker to its board of directors.
ADVENTRX Pharmaceuticals, Inc. (NYSEAMEX:ANX), Galena Biopharma Inc (NASDAQ:GALE), Sangamo Biosciences, Inc. (NASDAQ:SGMO), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and ImmunoGen, Inc. (NASDAQ:IMGN) all gained between 1-2%.
More on the gaining side were Sequenom, Inc. (NASDAQ:SQNM), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Gilead Sciences, Inc. (NASDAQ:GILD) and Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR).
Surprisingly, YM BioSciences Inc. (USA) (NYSEAMEX:YMI) and MannKind Corporation (NASDAQ:MNKD) closed with no change on Friday.
On the flip side, ArQule, Inc. (NASDAQ:ARQL) was the biggest loser among biotech stocks on failure of colorectal drug Tivantinib.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) lost 8.53%, limiting its weekly gain to 7.82% and performance in 2013 to 44%.
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) and Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) all fell after their presentations at the 31st Annual J.P. Morgan Healthcare Conference.
Inovio Pharmaceuticals, Inc. (NYSEAMEX:INO) scored second decline in a row on collaboration with MVI for development of malaria vaccine.
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) was down after unveiling plans for 2013 and an update on its performance in 2012.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Peregrine Pharmaceuticals (NASDAQ:PPHM), Illumina, Inc. (NASDAQ:ILMN), Celsion Corporation (NASDAQ:CLSN) and VIVUS, Inc. (NASDAQ:VVUS) all retreated between 1-2%.
More on the downside were Amgen, Inc. (NASDAQ:AMGN), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Complete Genomics, Inc. (NASDAQ:GNOM) and Biogen Idec Inc. (NASDAQ:BIIB).